Portal de recerca
BENEFIT 15 ESTUDIO DE SEGUIMIENTO A LARGO PLAZO DEL ESTUDIO BENEFIT Y DE LOS ESTUDIOS DE SEGUIMIENTO DE BENEFIT.
Dades bàsiques
- Protocol:
- BAY86-5046/19215
- EURDRACT:
- 2017-001176-31
- NCT:
- Centre:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Any inici:
- 2017
- Any de finalització:
Documents
- No hi ha documents
Participants
Grups d'Investigació
Finançadors - Promotors
Resultats de l'Assaig Clínic
Acute cerebral haematoma in the course of herpes simplex 1 encephalitis. A rare complication.
Veiga Canuto D; (...); Quiroz Tejada A
Letter. 10.1016/j.nrl.2019.12.002. 2021
An algorithm to predict intrathecal synthesis of IgG with high efficiency
Tortosa-Carreres, Jordi; (...); Casanova, Bonaventura
Meeting Abstract. 2023
An expanded parenchymal CD8+ T cell clone in GABA A receptor encephalitis.
Bracher A; (...); Dornmair K
Article. 10.1002/acn3.50974. 2020
Anti-CD20 monoclonal antibodies in primary progressive multiple sclerosis: a real-life comparative study of rituximab vs. ocrelizumab
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Assessment of Plasma and Cerebrospinal Fluid Biomarkers in Different Stages of Alzheimer's Disease and Frontotemporal Dementia.
Álvarez-Sánchez L; (...); Cháfer-Pericás C
Article. 10.3390/ijms24021226. 2023
Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis.
Lunemann JD; (...); Comabella M
Article. 10.1212/NXI.0000000000200270. 2024
Association of Serum Neurofilament Light Chain Levels at Disease Onset With Disability Worsening in Patients With a First Demyelinating Multiple Sclerosis Event Not Treated With High-Efficacy Drugs.
Monreal, Enric; (...); Villar LM
Article. 10.1001/jamaneurol.2023.0010. 2023
Autologous hematopoietic stem cell transplantation in multiple sclerosis: updating outcomes in the Valencian cohort.
Boix Lago, A.; (...); Casanova Estruch, B.
Meeting Abstract. 2023
Automated Cervical Spinal Cord Segmentation in Real-World MRI of Multiple Sclerosis Patients by Optimized Hybrid Residual Attention-Aware Convolutional Neural Networks
Bueno, America; (...); Alberich-Bayarri, Angel
Article. 10.1007/s10278-022-00637-4. 2022
Basal levels of serum neurofilament light in normal aging and multiple sclerosis patients
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Brain atrophy in relapsing optic neuritis is associated to anti-mog antibodies
Navarro Canto, L.; (...); Casanova Estruch, B.
Meeting Abstract. 2019
Brain Atrophy in Relapsing Optic Neuritis Is Associated With Crion Phenotype
Canto, LN; (...); Estruch, BC
Article. 10.3389/fneur.2019.01157. 2019
Brain region volumes and their relationship with disability progression and cognitive function in primary progressive multiple sclerosis.
Perez-Miralles, Francisco Carlos; (...); Casanova, Bonaventura
Article. 10.1002/brb3.2044. 2021
Brain signal intensity changes as biomarkers in amyotrophic lateral sclerosis
Vazquez-Costa, JF; (...); Sevilla, T
Article. 10.1111/ane.12863. 2018
Carretera perdida: imagen de la degeneracion neuronal secundaria
Montoya-Filardi, A.; (...); Polo, J. Carreres
Article. 10.1016/j.rx.2022.01.008. 2022
Case Report: Exacerbation of Relapses Following mRNA COVID-19 Vaccination in Multiple Sclerosis: A Case Series.
Quintanilla-Bordás C; (...); Casanova B
Article. 10.3389/fneur.2022.897275. 2022
Cavernous Sinus Thrombosis Secondary to Streptococcus Constellatus Pharynges
Jaramillo-Angel, Natalia; (...); Carceller, Miguel Armengot
Article. 10.1007/s12070-024-04511-3. 2024
Cerebrospinal fluid kappa free light chains and IgM index for diagnosis and prognosis in multiple sclerosis
Gil-Perotin, S.; (...); Casanova, B.
Meeting Abstract. 2021
Cervical spinal cord T2 lesions independently predict early conversion to secondary progressive multiple sclerosis: a longitudinal 10-year study
Lacruz-Ballester, L.; (...); Casanova-Estruch, B.
Meeting Abstract. 2021
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: DISCOVER study
Oreja-Guevara, Celia; (...); Rio, Jordi
Article. 10.1016/j.msard.2024.105787. 2024
Clinical trajectories of patients with multiple sclerosis from onset and their relationship with serum neurofilament light chain levels
Quintanilla-Bordas, Carlos; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2024.1477335. 2024
Cognitive impairment in multiple sclerosis: diagnosis and monitoring.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-021-05165-7. 2021
Cognitive performance and health-related quality of life in patients with neuromyelitis optica spectrum disorder
Lopez-Soley, Elisabet; (...); Solana, Elisabeth
Meeting Abstract. 2022
Cognitive Performance and Health-Related Quality of Life in Patients with Neuromyelitis Optica Spectrum Disorder.
Lopez-Soley E; (...); Solana E
Article. 10.3390/jpm12050743. 2022
Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis.
Gil-Perotin S; (...); Casanova B
Article. 10.3389/fneur.2019.01008. 2019
Comparative Assessment of Simoa and Lumipulse for Measuring Serum Neurofilament Light Chain in Multiple Sclerosis Patients
Gasque-Rubio, Raquel; (...); Perez-Miralles, Francisco
Article. 10.1155/2024/1950913. 2024
Consensus document on the multidisciplinary management of neurogenic lower urinary tract dysfunction in patients with multiple sclerosis.
Medina-Polo J; (...); López-Fando L
Article. 10.1002/nau.24276. 2020
Consensus guidelines for the timely detection and diagnosis of disease progression in multiple sclerosis patients
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Consensus on early detection of disease progression in patients with multiple sclerosis
Meca-Lallana, Jose E.; (...); Oreja-Guevara, Celia
Article. 10.3389/fneur.2022.931014. 2022
Cross-reactivity of a pathogenic autoantibody to a tumor antigen in GABA A receptor encephalitis.
Brändle SM; (...); Dornmair K
Article. 10.1073/pnas.1916337118. 2021
CSF chitinase 3-like-1 association with disability of primary progressive MS
Perez-Miralles, F; (...); Casanova, B
Article. 10.1212/NXI.0000000000000815. 2020
Changes in Brain Volume in Specific Regions could be related to Disability Progression in Primary Progressive Multiple Sclerosis Patients
Miralles, FP; (...); Casanova, B
Meeting Abstract. 2019
Changes in brain volume in specific regions could predict worsening cognition in primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Characterization of the gait in patients with relapsing-remitting multiple sclerosis and secondary progressive multiple sclerosis measured by FeetMe (R) integrated sensor insole system: Results of the interim analysis
Izquierdo Ayuso, G.; (...); Casanova Estruch, B.
Meeting Abstract. 2021
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2018
Chitinase-3-like protein 1 could be a predictor of disability progression in patients with primary progressive multiple sclerosis: A one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Chronic hyperammonemia induces peripheral inflammation that leads to cognitive impairment in rats: reversal by anti-tnfa treatment.
Balzano T; (...); Felipo V
Article. 10.1016/j.jhep.2019.01.008. 2020
Deciphering Multiple Sclerosis Progression.
Meca-Lallana, Virginia; (...); Perez-Miralles, Francisco Carlos
Review. 10.3389/fneur.2021.608491. 2021
Design and Validation of an Expanded Disability Status Scale Model in Multiple Sclerosis.
Barreiro-Gonzalez, Antonio; (...); Casanova, Bonaventura
Article. 10.1159/000519772. 2022
Different clinical response to interferon beta and glatiramer acetate related to the presence of oligoclonal IgM bands in CSF in multiple sclerosis patients
Casanova, B; (...); Coret, F
Article. 10.1007/s10072-018-3442-y. 2018
DISCOVER STUDY, FIRST ANALYSIS SPECIFIC FOR SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS BURDEN AND COST IN SPAIN: INTERIM ANALYSIS RESULTS
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology.
Brieva, Luis; (...); Moral, Ester
Article. 10.1016/j.msard.2022.103805. 2022
Disturbed Glucose Metabolism in Rat Neurons Exposed to Cerebrospinal Fluid Obtained from Multiple Sclerosis Subjects
Mathur, D; (...); Burgal-Marti, M
Article. 10.3390/brainsci8010001. 2018
Does benign multiple sclerosis exist?
Verdini Martinez, Laura; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dynamic 18F-FDG PET to detect differences among patients with progressive and relapsing multiple sclerosis: a pilot study
Quintanilla Bordas, Carlos; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Dyschromatopsia in multiple sclerosis reflects diffuse chronic neurodegeneration beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1007/s13760-020-01516-x. 2020
Early Alzheimer's Disease Screening Approach Using Plasma Biomarkers
Alvarez-Sanchez, Lourdes; (...); Chafer-Pericas, Consuelo
Article. 10.3390/ijms241814151. 2023
Early beginning of alemtuzumab: Changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study.
Meca-Lallana, J E; (...); Calles Hernandez, C
Article. 10.1016/j.nrleng.2021.06.006. 2023
Early beginning of alemtuzumab: changing the multiple sclerosis treatment paradigm. Interim analysis of the LEMVIDA study
Meca-Lallana, J. E.; (...); Hernandez, C. Calles
Article. 10.1016/j.nrl.2021.06.007. 2024
Economic impact and clinical profile of the secondary progressive multiple sclerosis (SPMS) patient: the DISCOVER study
Oreja-Guevara, C.; (...); Meca-Lallana, J. E.
Meeting Abstract. 2021
Economic impact of the secondary progressive multiple sclerosis in spain: interim analysis of the discover study
Oreja-Guevara, C; (...); Meca-Lallana, J
Meeting Abstract. 2020
Eculizumab for a catastrophic relapse in NMOSD: case report.
Gorriz, David; (...); Casanova, Bonaventura
Article. 10.1007/s10072-023-06971-x. 2023
Effectiveness and Safety of Teriflunomide in Relapsing-Remitting Multiple Sclerosis and Improvements in Quality of Life: Results from the Real-World TERICARE Study.
Meca-Lallana JE; (...); Llarena C
Article. 10.1007/s40120-023-00557-7. 2023
Effectiveness of rituximab vs. ocrelizumab for the treatment of primary progressive multiple sclerosis: a real-world observational study.
Alcala, Carmen; (...); Casanova, Bonaventura
Article. 10.1007/s00415-022-10989-0. 2022
Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-018-8899-3. 2018
Elevation of Chi3l1 in acute disseminated encephalomyelitis: implications in pathogenesis
Gil-Perotin, S; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Elevation of serum neurofilament light-chain levels disclose possible occult progressive multifocal leukoencephalopathy and immune reconstitution syndrome in a patient receiving ozanimod: a case report.
Quintanilla-Bordás C; (...); Pérez-Miralles FC
Case Reports. 10.3389/fimmu.2024.1465678. 2024
Escalation vs. Early Intense Therapy in Multiple Sclerosis.
Casanova, Bonaventura, Quintanilla-Bordas, Carlos, Gascon, Francisco
Article. 10.3390/jpm12010119. 2022
Evaluating the complement C1q levels in serum and cerebrospinal fluid in multiple sclerosis patients: Could it serve as a valuable marker in clinical practice?
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.jneuroim.2024.578428. 2024
Glioblastoma versus solitary brain metastasis: MRI differentiation using the edema perfusion gradient
Aparici-Robles F; (...); Miguel Garcia-Gomez, Juan
Article. 10.1111/jon.12920. 2021
High Levels of Cerebrospinal Fluid Kappa Free Light Chains Relate to IgM Intrathecal Synthesis and Might Have Prognostic Implications in Relapsing Multiple Sclerosis.
Castillo-Villalba, Jessica; (...); Casanova, Bonaventura
Article. 10.3389/fimmu.2022.827738. 2022
Imaging of post-traumatic hearing loss.
Mazon, M; (...); Mas-Estelles, F
Article. 10.1016/j.rx.2017.07.005. 2018
Immune tolerance in multiple sclerosis and neuromyelitis optica with peptide-loaded tolerogenic dendritic cells in a phase 1b trial
Zubizarreta, I; (...); Villoslada, P
Article. 10.1073/pnas.1820039116. 2019
Immune tolerance in patients with Multiple Sclerosis and Neuromyelitis Optica by peptide-loaded tolerogenic dendritic cells: final results of the phase 1b clinical trial and extension
Zubizarreta, I; (...); Villoslada, P
Meeting Abstract. 2019
Impact of Neuromyelitis Optica Spectrum Disorder on Quality of Life from the Patients' Perspective: An Observational Cross-Sectional Study
Meca-Lallana, Jose E.; (...); Maurino, Jorge
Article. 10.1007/s40120-022-00356-6. 2022
Impact of neuromyelitis optica spectrum disorder on quality of life: Assessing the patients' perspective
Meca-Lallana, Jose; (...); Maurino, Jorge
Meeting Abstract. 10.1016/j.jns.2021.118844. 2021
Impact of stigma in patients with primary progressive multiple sclerosis: a one-year follow-up
Perez-Miralles, F; (...); Casanova, B
Meeting Abstract. 2019
Improvements in Quality of Life of Patients with Multiple Sclerosis receiving Alemtuzumab in Clinical Practice: LEMVIDA study
Meca Lallana, Jose; (...); Forner, Mireia
Meeting Abstract. 10.1212/WNL.0000000000202381. 2023
Improvements in quality of life of patients with multiple sclerosis receiving alemtuzumab in clinical practice: the LEMVIDA study.
Meca-Lallana, Jose Eustasio; (...); Toledo, Baldo
Article. 10.1186/s41687-024-00822-9. 2024
Improving the efficiency of free kappa light chains as diagnostic biomarker of Multiple Sclerosis by using a novel algorithm.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2023.104997. 2023
Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis
Comabella, Manuel; (...); Luenemann, Jan D.
Article. 10.1007/s00415-024-12763-w. 2025
Intracranial subarachnoid fat and hemorrhage secondary to sacral fracture with spondylopelvic dissociation.
Polo, JC, Martinez, MVA, Mateos, DS
Article. 10.1016/j.rx.2017.05.001. 2017
Is it cost-effective to request IgM oligoclonal bands against lipids in daily practice as a biomarker for poor prognosis in multiple sclerosis?
Ribes Garcia, Sara; (...); Bonaventura, Casanova Estruch
Article. 10.1016/j.msard.2023.105033. 2023
Leptomeningeal gadolinium enhancement in multiple sclerosis
Gascon-Gimenez, F; (...); Casanova, V
Meeting Abstract. 2019
Leptomeningeal gadolinium enhancement lesions in multiple sclerosis are not related to different brain volume measures
Garcia, F; (...); Casanova, B
Meeting Abstract. 2018
Long-term efficacy of alemtuzumab in multiple sclerosis: a real word multicenter Spanish experience
Rubio Alcantud, Almudena; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Magnetic resonance imaging and optical coherence tomography correlations in multiple sclerosis beyond anatomical landmarks.
Barreiro-González A; (...); Casanova B
Article. 10.1016/j.jns.2020.117180. 2020
Management of iodine contrast induced salivary gland swelling (sialadenitis): experiences from an observational study.
Saro-Buendía M; (...); Armengot Carceller M
Article. 10.1080/00016489.2022.2162121. 2023
Milestones of Precision Medicine: An Innovative, Multidisciplinary Overview
Garcia-Foncillas, J; (...); Gomez, MVP
Review. 10.1007/s40291-021-00544-4. 2021
miRNA Signature in CSF From Patients With Primary Progressive Multiple Sclerosis.
Munoz-San Martin, Maria; (...); Ramio-Torrenta, Lluis
Article. 10.1212/NXI.0000000000200069. 2023
Neuromyelitis optica associated with the use of Atezolizumab in a patient with advanced lung adenocarcinoma.
Pedrero Prieto, Manuel; (...); Casanova Estruch, Bonaventura
Article. 10.1007/s10072-023-07252-3. 2023
New Algorithms Improving PML Risk Stratification in MS Patients Treated With Natalizumab.
Toboso I; (...); Villar LM
Article. 10.3389/fneur.2020.579438. 2020
NFL during acute spinal cord lesions in MS: a hurdle for the detection of inflammatory activity.
Alcala, C.; (...); Casanova, B.
Article. 10.1007/s00415-021-10926-7. 2022
Oligoclonal M bands and cervical spinal cord lesions predict early secondary progressive multiple sclerosis.
Alcala Vicente, Carmen; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2022.991596. 2022
Oligoclonal M bands distinguish two MS populations based on neurofilament light chain levels in patients without inflammatory activity
Castillo, J.; (...); Casanova, B.
Meeting Abstract. 2022
Oligoclonal M bands unveil occult inflammation in multiple sclerosis.
Casanova B; (...); Pérez-Miralles F
Article. 10.1016/j.msard.2022.104118. 2022
Onset of secondary progressive multiple sclerosis is not influenced by current relapsing multiple sclerosis therapies.
Coret F; (...); Casanova B
Article. 10.1177/2055217318783347. 2018
Perception of Stigma in Patients with Neuromyelitis Optica Spectrum Disorder
Meca-Lallana, JE; (...); Maurino, J
Article. 10.2147/PPA.S305707. 2021
Perception of stigma in patients with primary progressive multiple sclerosis.
Pérez-Miralles F; (...); Casanova-Estruch B
Article. 10.1177/2055217319852717. 2019
Perception of stigma in people with neuromyelitis optica spectrum disorders (PERSPECTIVES-NMO Study)
Lallana, Jose Meca; (...); Maurino, Jorge
Meeting Abstract. 2021
Peripapillary retinal nerve fibre layer correlates better with spinal cord volume than with brain parenchymal fraction in multiple sclerosis
Barreiro-Gonzalez, A; (...); Casanova, B
Meeting Abstract. 2019
Post-stapedectomy intravestibular luxation of the stapes
Fornas, Marta Navarro, Vernetta, Carlos de Paula, Polo, Joan Carreres
Editorial Material. 10.1016/j.otorri.2021.08.001. 2022
Post-stapedectomy intravestibular luxation of the stapes.
Navarro Fornas, Marta, de Paula Vernetta, Carlos, Carreres Polo, Joan
Editorial Material. 10.1016/j.otoeng.2022.07.001. 2022
Potential Biomarkers Associated with Multiple Sclerosis Pathology.
Mathur, Deepali; (...); Casanova, Bonaventura
Article. 10.3390/ijms221910323. 2021
Potential Role of CHI3L1+ Astrocytes in Progression in MS.
Cubas-Núñez L; (...); Casanova B
Article. 10.1212/NXI.0000000000000972. 2021
Predictive potential of serum and cerebrospinal fluid biomarkers for disease activity in treated multiple sclerosis patients.
Tortosa-Carreres J; (...); Pérez-Miralles FC
Article. 10.1016/j.msard.2024.105734. 2024
Predictive value of isolated CSF NfL and Chi3l1 measures in clinical practice
Gil-Perotin, S; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: A Case Report
Gil-Perotin, S; (...); Casanova-Estruch, B
Article. 10.3389/fneur.2018.00340. 2018
Quantifying the patient ' s perspective in neuromyelitis optica spectrum disorder: Psychometric properties of the SymptoMScreen questionnaire
Meca-Lallana, JE; (...); Ballesteros, J
Article. 10.1371/journal.pone.0255317. 2021
Quantifying the patient's perspective in neuromyelitis optica spectrum disorders: design of a multicenter, non-interventional study
Meca-Lallana, J; (...); Maurino, J
Meeting Abstract. 2020
Radiological evaluation of the postsurgical middle ear.
Mazon, M.; (...); Carreres-Polo, J.
Article. 10.1016/j.rx.2021.04.005. 2021
Radiological evaluation of the postsurgical middle ear.
Mazón M; (...); Carreres-Polo J
Article. 10.1016/j.rxeng.2021.04.006. 2021
Recommendations for the Diagnosis and Treatment of Multiple Sclerosis Relapses.
Ramo-Tello, Cristina; (...); Rovira À
Article. 10.3390/jpm12010006. 2021
Recurrent and universal alopecia areata following alemtuzumab treatment in multiple sclerosis: A secondary autoimmune disease
Alcala, C; (...); Casanova, B
Editorial Material. 10.1016/j.msard.2018.12.005. 2019
Renal function influences serum neurofilament light chain levels in patients with multiple sclerosis
Gasque Rubio, R.; (...); Casanova Estruch, B.
Meeting Abstract. 2022
Renal function's impact on serum neurofilament levels in patients with multiple sclerosis: an exploratory analysis.
Tortosa-Carreres, Jordi; (...); Perez-Miralles, Francisco
Article. 10.1007/s10072-024-07772-6. 2024
Role of Imaging in pseudotumor cerebri syndrome
Veiga-Canuto, D, Carreres-Polo, J
Article. 10.1016/j.rx.2020.05.007. 2020
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry.
Arrambide, Georgina; (...); Meca-Lallana, Jose E
Article. 10.1212/NXI.0000000000001024. 2021
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis.
Fissolo, Nicolas; (...); Comabella, Manuel
Article. 10.1136/jnnp-2023-332251. 2023
Serum biomarkers at disease onset for personalized therapy in multiple sclerosis.
Monreal E; (...); Villar LM
Article. 10.1093/brain/awae260. 2024
Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels at Disease Onset for Prediction of the Risk of Disability Worsening in Patients with Multiple Sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2023
Serum neurofilament light chain and glial fibrillary acidic protein levels at disease onset unveil immunological pathways of disability acquisition in multiple sclerosis
Monreal, Enric; (...); Villar Guimerans, Luisa Maria
Meeting Abstract. 2024
Serum Neurofilament Light Chain is a surrogate marker of NEDA-3 in Multiple Sclerosis
Gascon Gimenez, Francisco Guillermo; (...); Casanova, Bonaventura
Meeting Abstract. 2023
Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study).
Pérez-Miralles F; (...); Casanova B
Article. 10.1016/j.msard.2021.102860. 2021
Silent Progression or Bout Onset Progressive Multiple Sclerosis?
Gil-Perotin, S; (...); Casanova, B
Letter. 10.1002/ana.25537. 2019
Spinal cord atrophy but not brain atrophy measures, correlates with the Multiple Sclerosis Severity Score
Carratala, S; (...); Estruch, BC
Meeting Abstract. 2018
Sustained hyperammonemia induces TNF-a IN Purkinje neurons by activating the TNFR1-NF-?B pathway.
Balzano T; (...); Felipo V
Article. 10.1186/s12974-020-01746-z. 2020
Symptom severity in Neuromyelitis Optica Spectrum Disorder from the patients' perspective
Meca-Lallana, J.; (...); Maurino, J.
Meeting Abstract. 2021
The impact of stigma in people with primary progressive multiple sclerosis
Perez-Miralles, F; (...); Casanova-Estruch, B
Meeting Abstract. 2018
Tracheobronchial Laceration After Blunt Chest Trauma.
Veiga Canuto D, Carreres Polo J
Article. 10.1016/j.arbres.2019.11.029. 2021
Tracheobronchial Laceration After Blunt Chest Trauma.
Veiga-Canuto D, Carreres-Polo J
Article. 10.1016/j.arbr.2021.05.007. 2021
Transient reduced diffusion on magnetic resonance imaging due to transneuronal degeneration of the striatum.
Belloch-Ripollés V, Carreres-Polo J
Case Reports. 10.33588/rn.7504.2022035. 2022
Transient restriction of diffusion in magnetic resonance imaging due to transneuronal degeneration of the corpus striatum
Belloch Ripolles, Vicente, Carreres-Polo, Joan
Editorial Material. 2022
Treatment of multiple sclerosis with Rituximab: a multicenter Spanish experience
Alcala, C.; (...); Casanova, B.
Meeting Abstract. 2021
Treatment of multiple sclerosis with rituximab: A Spanish multicenter experience.
Gascon-Gimenez, Francisco; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2023.1060696. 2023
Treatment of Multiple Sclerosis With Teriflunomide. Multicenter Study of Real Clinical Practice in the Valencian Community-Spain.
Landete, Lamberto; (...); Casanova, Bonaventura
Article. 10.3389/fneur.2021.727586. 2021
Treatment with alemtuzumab after fingolimod in relapsing-remitting multiple sclerosis is effective and safe
Alcala, C; (...); Casanova, B
Meeting Abstract. 2018
Treatment with alemtuzumab or rituximab after fingolimod withdrawal in relapsing-remitting multiple sclerosis is effective and safe
Alcala, C; (...); Casanova, B
Article. 10.1007/s00415-019-09195-2. 2019
Usefulness of susceptibility-weighted imaging in subacute cerebral fat embolism
Gil-Perotin, S, Carreres-Polo, J
Letter. 10.1016/j.nrleng.2019.01.005. 2019